glutamine and Leukemia, Myelomonocytic, Acute

glutamine has been researched along with Leukemia, Myelomonocytic, Acute in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Auberger, P; Bardet, V; Bouscary, D; Chapuis, N; Green, AS; Ifrah, N; Jacque, N; Jacquel, A; Kosmider, O; Lacombe, C; Lambert, M; Maciel, TT; Mayeux, P; Moura, IC; Neveux, N; Poulain, L; Radford-Weiss, I; Schmitt, A; Tamburini, J; Uzunov, M; Willems, L	1
Boltz-Nitulescu, G; Fuegger, R; Goetzinger, P; Holzer, S; Leutmezer, F; Oehler, R; Rath, V; Reissner, CM; Roth, E; Spittler, A; Wrba, F	1

Other Studies

2 other study(ies) available for glutamine and Leukemia, Myelomonocytic, Acute

Article	Year
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood, 2013, Nov-14, Volume: 122, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Amino Acid Transport System ASC; Animals; Apoptosis; Asparaginase; Autophagy; Bacterial Proteins; Biological Transport; Cell Line, Tumor; Dickeya chrysanthemi; Drug Screening Assays, Antitumor; Escherichia coli Proteins; Female; Glutaminase; Glutamine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Middle Aged; Minor Histocompatibility Antigens; Multiprotein Complexes; Protein Biosynthesis; RNA Interference; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays; Young Adult	2013
Low glutamine concentrations induce phenotypical and functional differentiation of U937 myelomonocytic cells. The Journal of nutrition, 1997, Volume: 127, Issue:11 Topics: Antibodies, Monoclonal; Antigens, Surface; Base Sequence; Blotting, Northern; Cell Differentiation; Cell Division; Cell Line; DNA Primers; Dose-Response Relationship, Drug; Escherichia coli; Flow Cytometry; Glutamine; Histiocytes; Humans; Leukemia, Myelomonocytic, Acute; Microspheres; Monocytes; Ornithine; Phagocytosis; Phenotype; Receptors, IgE; Receptors, IgG; Time Factors	1997

Article

Year

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Blood, 2013, Nov-14, Volume: 122, Issue:20

Topics: Adult; Aged; Aged, 80 and over; Amino Acid Transport System ASC; Animals; Apoptosis; Asparaginase; Autophagy; Bacterial Proteins; Biological Transport; Cell Line, Tumor; Dickeya chrysanthemi; Drug Screening Assays, Antitumor; Escherichia coli Proteins; Female; Glutaminase; Glutamine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Middle Aged; Minor Histocompatibility Antigens; Multiprotein Complexes; Protein Biosynthesis; RNA Interference; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays; Young Adult

2013

Low glutamine concentrations induce phenotypical and functional differentiation of U937 myelomonocytic cells.

The Journal of nutrition, 1997, Volume: 127, Issue:11

Topics: Antibodies, Monoclonal; Antigens, Surface; Base Sequence; Blotting, Northern; Cell Differentiation; Cell Division; Cell Line; DNA Primers; Dose-Response Relationship, Drug; Escherichia coli; Flow Cytometry; Glutamine; Histiocytes; Humans; Leukemia, Myelomonocytic, Acute; Microspheres; Monocytes; Ornithine; Phagocytosis; Phenotype; Receptors, IgE; Receptors, IgG; Time Factors

1997